Literature DB >> 17272396

Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway.

Armina A Kazi1, Robert D Koos.   

Abstract

Vascular endothelial growth factor (VEGF) plays an essential role in normal uterine physiology and function as well as endometrial cancer and other uterine disorders. Recently we showed that estrogen regulation of VEGF expression in the rat uterus involves rapid recruitment of both estrogen receptor (ER)-alpha and hypoxia-inducible factor (HIF)-1alpha to the VEGF promoter. Estrogen is known to stimulate both the MAPK and phosphatidylinositol 3-kinase (PI3K) pathways, which have been linked to the activation of both of these transcription factors. Therefore, the involvement of these pathways in estrogen-induced VEGF expression was investigated. Inhibitors of the MAPK (U0126) or PI3K pathways (wortmannin or LY294002) were administered ip to immature female rats 1 h before 17beta-estradiol (E(2)) treatment. E(2) activation of both pathways occurred and was completely inhibited by the appropriate antagonist. Only PI3K inhibitors, however, blocked E(2) stimulation of VEGF mRNA expression and E(2)-induced uterine edema. In vivo chromatin immunoprecipitation analysis showed that this was associated with a failure of both HIF-1alpha and ERalpha to bind to the VEGF promoter. To determine whether inhibiting the PI3K pathway affected ERalpha induction of other estrogen target genes, the expression of creatine kinase B and progesterone receptor A/B was also examined. The expression of each was also inhibited by wortmannin, as was ERalpha binding to the creatine kinase B promoter. In conclusion, although estrogen activates both the MAPK and PI3K pathways in the rat uterus, activation of HIF-1alpha and ERalpha, and therefore regulation of VEGF gene expression is dependent only on the PI3K/Akt pathway. Furthermore, activation of the PI3K pathway appears to be a common requirement for the expression of estrogen-induced genes. These findings not only shed light on estrogen action in normal target tissues but also have important implications for cancer biology because excessive PI3K, HIF-1alpha, and VEGF activity are common in estrogen-dependent tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272396     DOI: 10.1210/en.2006-1394

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  43 in total

1.  Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus.

Authors:  Adama Sidibé; Helena Polena; Jeremy Razanajatovo; Tiphaine Mannic; Nicolas Chaumontel; Soumalamaya Bama; Irène Maréchal; Philippe Huber; Danielle Gulino-Debrac; Laurence Bouillet; Isabelle Vilgrain
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

2.  Correlation between genetic polymorphisms within the MAPK1/HIF-1/HO-1 signaling pathway and risk or prognosis of perimenopausal coronary artery disease.

Authors:  Nan Guo; Nan Zhang; Liqiu Yan; Xufen Cao; Jiawang Wang; Yunfei Wang
Journal:  Clin Cardiol       Date:  2017-04-26       Impact factor: 2.882

3.  Deletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility.

Authors:  Yoshihiro Tanaka; Joo Hyun Park; Pradeep S Tanwar; Tomoko Kaneko-Tarui; Shilpi Mittal; Ho-Joon Lee; Jose M Teixeira
Journal:  Endocrinology       Date:  2011-11-29       Impact factor: 4.736

4.  Arsenite stabilizes HIF-1α protein through p85α-mediated up-regulation of inducible Hsp70 protein expression.

Authors:  Wei Guo; Zhuo Yang; Qing Xia; Jinyi Liu; Yonghui Yu; Jingxia Li; Zhenghong Zuo; Dongyun Zhang; Xueyong Li; Xianglin Shi; Chuanshu Huang
Journal:  Cell Mol Life Sci       Date:  2010-09-12       Impact factor: 9.261

5.  Physical and functional interactions between Runx2 and HIF-1α induce vascular endothelial growth factor gene expression.

Authors:  Tae-Geon Kwon; Xiang Zhao; Qian Yang; Yan Li; Chunxi Ge; Guisheng Zhao; Renny T Franceschi
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

6.  Estrogen receptor-alpha overexpression suppresses 17beta-estradiol-mediated vascular endothelial growth factor expression and activation of survival kinases.

Authors:  Shameena Bake; Lijiang Ma; Farida Sohrabji
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

7.  HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland.

Authors:  N Ogba; Y Q Doughman; L J Chaplin; Y Hu; M Gargesha; M Watanabe; M M Montano
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

8.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Authors:  Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

9.  Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus.

Authors:  Armina A Kazi; Kristin Happ Molitoris; Robert D Koos
Journal:  Biol Reprod       Date:  2009-05-06       Impact factor: 4.285

10.  Inhibition of oxygen-induced hypoxia-inducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro.

Authors:  Kristin Happ Molitoris; Armina A Kazi; Robert D Koos
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.